Nucl Med Mol Imaging.  2009 Feb;43(1):10-18.

Evaluation of Multiple System Atrophy and Early Parkinson's Disease Using (123)I-FP-CIT SPECT

Affiliations
  • 1Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Korea. yk3181@snu.ac.kr
  • 2Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Korea.

Abstract

PURPOSE: We investigated quantification of dopaminergic transporter (DAT) and serotonergic transporter (SERT) on (123)I-FP-CIT SPECT for differentiating between multiple systemic atrophy (MSA) and idiopathic Parkinson's disease (IPD).
MATERIALS AND METHODS
N-fluoropropyl-2beta-carbomethoxy-3beta-4-[(123)I]-iodophenylnortropane SPECT ((123)I-FP-CIT SPECT) was performed in 8 patients with MSA (mean age: 64.0+/-4.5yrs, m:f=6:2), 13 with early IPD (mean age: 65.5+/-5.3yrs, m:f=9:4), and 12 healthy controls (mean age: 63.3+/-5.7yrs, m:f=8:4). Standard regions of interests (ROIs) of striatum to evaluate DAT, and hypothalamus and midbrain for SERT were drawn on standard template images and applied to each image taken 4 hours after radiotracer injection. Striatal specific binding for DAT and hypothalamic and midbrain specific binding for SERT were calculated using region/reference ratio based on the transient equilibrium method. Group differences were tested using ANOVA with the postHoc analysis.
RESULTS
DAT in the whole striatum and striatal subregions were significantly decreased in both patient groups with MSA and early IPD, compared with healthy control (p<0.05 in all). In early IPD, a significant increase in the uptake ratio in anterior and posterior putamen and a trend of increase in caudate to putamen ratio was observed. In MSA, the decrease of DAT was accompanied with no difference in the striatal uptake pattern compared with healthy controls. Regarding the brain regions where (123)I-FP-CIT binding was predominant by SERT, MSA patients showed a decrease in the binding of (123)I-FP-CIT in the pons compared with controls as well as early IPD patients (MSA: 0.22+/-0.1 healthy controls: 0.33+/-0.19, IPD: 0.29+/-0.19), however, it did not reach the statistical significance.
CONCLUSION
In this study, the differential patterns in the reduction of DAT in the striatum and the reduction of pontine (123)I- FP-CIT binding predominant by SERT could be observed in MSA patients on (123)I- FP-CIT SPECT. We suggest that the quantification of SERT as well as DAT using (123)I- FP-CIT SPECT is helpful to differentiate parkinsonian disorders in early stage.

Keyword

(123)I-FP-CIT; SPECT; dopamine transporter; serotonin transporter; idiopathic Parkinson's disease; multiple system atrophy

MeSH Terms

Atrophy
Brain
Dopamine Plasma Membrane Transport Proteins
Humans
Hypothalamus
Mesencephalon
Multiple System Atrophy
Parkinson Disease
Parkinsonian Disorders
Pons
Putamen
Serotonin Plasma Membrane Transport Proteins
Tomography, Emission-Computed, Single-Photon
Tropanes
Dopamine Plasma Membrane Transport Proteins
Serotonin Plasma Membrane Transport Proteins
Tropanes
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr